Core Insights - IBI Ag successfully completed its Series A funding round, raising a total of $10 million to advance its bioinsecticide platform [1][3]. Funding Details - The investment was led by Corteva through its Corteva Catalyst platform, with participation from The Trendlines Group, Iron Nation, Consensus Business Group, and a grant from the Israel Innovation Authority, along with Bandera Capital and First Imagine Ventures [2]. Company Milestone - The completion of the Series A funding marks a significant milestone for IBI Ag, highlighting the global recognition of its innovative antibody-based bioinsecticide platform [3]. Technology Overview - IBI Ag's proprietary technology utilizes single-domain antibodies (nanobodies) to develop effective and selective biological insect control products, aimed at protecting high-value crops while minimizing environmental impact [4][6]. Leadership Statements - The CEO of IBI Ag expressed pride in gaining investor confidence and emphasized the company's readiness to bring its biological solutions to farmers globally, enhancing productivity and sustainability [5]. - A senior director at Corteva highlighted the collaboration as a means to deliver innovative and sustainable crop protection solutions [5].